drug_type
RELEVANT_DRUG
intervention_type
Biologic drug (monoclonal antibody)
drug_description
Humanized anti-HER2 monoclonal antibody that binds HER2 subdomain IV, inhibits ligand-independent signaling, promotes HER2 downregulation, and mediates ADCC.
nci_thesaurus_concept_id
C1647
nci_thesaurus_preferred_term
Trastuzumab
nci_thesaurus_definition
A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)
drug_mesh_term
Trastuzumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized anti-HER2 monoclonal antibody that binds HER2 extracellular domain IV (ERBB2), inhibits ligand-independent HER2 signaling, promotes receptor internalization/downregulation, suppresses downstream PI3K/AKT and MAPK pathways, and engages Fc receptors to mediate ADCC against HER2-overexpressing tumor cells.
drug_name
Trastuzumab
nct_id_drug_ref
NCT05720026